Read by QxMD icon Read

alzheimer lancet

Moyra E Mortby, Sandra E Black, Serge Gauthier, David Miller, Anton Porsteinsson, Eric E Smith, Zahinoor Ismail
The World Alzheimer Report 2016 estimated that 47 million people are living with dementia worldwide (Alzheimer's Disease International, 2016). In the inaugural World Health Organization Ministerial Conference on Global Action against Dementia, six of the top ten research priorities were focused on prevention, identification, and reduction of dementia risk, and on delivery and quality of care for people with dementia and their carers (Shah et al., 2016). While the Lancet Neurology Commission has suggested that even minor advances to delay progression or ameliorate symptoms might have substantial financial and societal benefits (Winblad et al...
February 2018: International Psychogeriatrics
The Lancet Neurology
No abstract text is available yet for this article.
December 2017: Lancet Neurology
The Lancet Neurology
No abstract text is available yet for this article.
February 2017: Lancet Neurology
The Lancet
No abstract text is available yet for this article.
December 3, 2016: Lancet
The Lancet Neurology
No abstract text is available yet for this article.
June 2016: Lancet Neurology
The Lancet Neurology
No abstract text is available yet for this article.
August 2015: Lancet Neurology
The Lancet Neurology
No abstract text is available yet for this article.
December 2014: Lancet Neurology
The Lancet Neurology
No abstract text is available yet for this article.
October 2014: Lancet Neurology
Thomas G Beach, Julie A Schneider, Lucia I Sue, Geidy Serrano, Brittany N Dugger, Sarah E Monsell, Walter Kukull
In 2012, florbetapir (F) (Amyvid) received US Food and Drug Administration approval as a diagnostic agent for detecting neuritic (β-amyloid) plaques in living patients. Although such approval is specifically not extended to the use of florbetapir as a single definitive diagnostic test for Alzheimer disease dementia (ADD), it is of considerable importance to examine its potential in this regard. To estimate the ability of florbetapir amyloid imaging to detect specified densities of postmortem-identified neuritic plaques, we used the data of Clark et al [Clark CM, Pontecorvo MJ, Beach TG, et al...
October 2014: Journal of Neuropathology and Experimental Neurology
L J Stovner, J M Hoff, S Svalheim, N E Gilhus
BACKGROUND: The Global Burden of Disease study (GBD) is a large international initiative to collect and systematize data on disease burden expressed in non-economic terms, to allow comparisons across different disease conditions and countries. OBJECTIVES: To use data from the large GBD 2010 database to determine the importance of neurological disorders in Norway, and to compare it with global data on the same disorders. MATERIALS AND METHODS: Relevant data were extracted from the Lancet publication from December 2012, and from the interactive website of the Institute of Health Metrics and Evaluation on GBD...
2014: Acta Neurologica Scandinavica. Supplementum
S Duke Han, Jonathan Gruhl, Laurel Beckett, Hiroko H Dodge, Nikki H Stricker, Sarah Farias, Dan Mungas
Alzheimer's disease (AD) is associated with a cascade of pathological events involving formation of amyloid-based neuritic plaques and tau-based neurofibrillary tangles, changes in brain structure and function, and eventually, cognitive impairment and functional disability. The precise sequence of when each of these disease markers becomes abnormal is not yet clearly understood. The present study systematically tested the relationship between classes of biomarkers according to a proposed model of temporal sequence by Jack et al...
December 2012: Brain Imaging and Behavior
Massimo Musicco, Alessandro Padovani, Sandro Sorbi, Elio Scarpini, Paolo Caffarra, Stefano Cappa, Francesca Clerici, Massimo Tabaton, Carlo Caltagirone, Vincenzo Bonavita, Amalia C Bruni, Giuseppe Bruno, Antonio Federico, Carlo Ferrarese, Camillo Marra, Benedetta Nacmias, Lucilla Parnetti, Carla Pettenati, Giuseppe Sorrentino, Fabrizio Tagliavini, Claudio Mariani
A panel of Italian neurologists of the Italian Society for the study of Dementias (SINDEM) discussed the recently proposed new lexicon for Alzheimer disease (AD) and the related diagnostic criteria for the different phases of the disease (Preclinical AD, prodromal AD and Alzheimer's dementia) (Dubois et al. in Lancet Neurol 6:734-746, 2007; in Lancet Neurol 9:1118-1127, 2010). The aim of this discussion was to reach a consensus, among the Italian neurologists involved in the study and care of persons with dementia, in particular in reference to the potential use of the proposed diagnostic criteria in clinical practice...
February 2012: Neurological Sciences
Natalie S Ryan, Martin N Rossor
With the prospect of prevention trials for familial Alzheimer's disease on the horizon, understanding the natural history of the illness has never been so important. Earlier this year in The Lancet Neurology, Acosta-Baena and colleagues published the results of the largest and longest retrospective study of pre-dementia clinical stages in familial Alzheimer's disease to date. By reviewing serial neuropsychological assessments of individuals from a large Colombian kindred affected by the E280A mutation in the Presenilin 1 gene, they defined three stages of pre-dementia cognitive impairment...
September 27, 2011: Alzheimer's Research & Therapy
M Day, P Chandran, F Luo, N R Rustay, S Markosyan, D LeBlond, G B Fox
Latrepirdine is hypothesized to exert a unique mechanism of action involving stabilization of mitochondria that may have utility in treating Alzheimer's disease. However, the ability of latrepirdine to improve cognition in Alzheimer's disease (AD) is controversial due to a discrepancy between the positive signal reported in the multi-site phase II clinical trial where latrepirdine met all primary and secondary endpoints [Doody et al. (2008) Lancet 372:207-215], and the subsequent null effect observed in a multicenter, phase III trial...
August 25, 2011: Neuroscience
P Frasson, R Ghiretti, E CatricalĂ , S Pomati, A Marcone, L Parisi, P M Rossini, S F Cappa, C Mariani, N Vanacore, F Clerici
The presence of episodic memory impairment is required for the diagnosis of Alzheimer's dementia by all current diagnostic criteria. The new research criteria proposed by Dubois et al. (Lancet Neurol 6:734-746, 2007) require that the impairment should not improve significantly with cueing, recognition testing nor after the control of effective encoding. This is considered to be the core deficit of "prodromal Alzheimer's disease". The Free and Cued Selective Reminding Test (FCSRT) is a memory test that allows in assessing these specific features of memory impairment...
December 2011: Neurological Sciences
Giovanni Augusto Carlesimo, Roberta Perri, Carlo Caltagirone
Aim of the present review paper was to evaluate the hypothesis (included in the proposal of new research criteria for Alzheimer's disease; Dubois et al., Lancet Neurology, 6, 734-746, 2007) that a neuropsychological tool which provides support for the semantic encoding of memorandum at the time of study and supplies category cues at the time of retrieval (i.e. the Grober-Buschke paradigm) is more effective than traditional measures of free recall in 1) differentiating patients affected by the amnestic form of Mild Cognitive Impairment (MCI) or by mild to moderate forms of Alzheimer's disease (AD) from healthy matches, 2) predicting the conversion of individuals with MCI to AD, and 3) differentiating AD patients from individuals affected by other forms of dementia...
March 2011: Neuropsychology Review
Roy W Jones
Dimebon (latrepirdine) has received widespread publicity as a potential therapy for Alzheimer's disease following a very positive phase 2 study carried out in Russia and published in the Lancet in 2008. In this study there were improvements over 6 months in all endpoints (cognitive, global, daily function and behaviour), with continuing improvement at 12 months in cognition and daily function. A more recent multinational phase 3 study, however, showed no improvements whatsoever and no difference between the two drug-treated groups and the placebo group...
September 13, 2010: Alzheimer's Research & Therapy
Lon S Schneider, Richard E Kennedy, Gary R Cutter
BACKGROUND: Low cerebrospinal fluid (CSF) amyloid-beta(1-42) concentration and high total-tau/Abeta(1-42) ratio have been recommended to support the diagnosis of prodromal Alzheimer's disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and also to select patients for clinical trials (Shaw et al, Ann Neurol 2009;65:403-13; Dubois et al, Lancet Neurol 2007;6:734-46). METHODS: We tested this recommendation with clinical trials simulations using patients from the Alzheimer Disease Neuroimaging Initiative who fulfilled the following entry criteria: (1) aMCI, (2) aMCI with CSF Abeta(1-42) <or=192 mg/mL, (3) and aMCI with total-tau/Abeta(1-42) >0...
September 2010: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Boyd H Davis, Charlene Pope
The ordinary social engagement of human life would not usually be considered an arena for language policy. Yet clinical evidence mounts that social interaction improves our lives as we age. Since social engagement decreases cardiovascular risks (Ramsay et al. in Ann Epidemiol 18:476-483, 2008) and delays memory loss among those living in communities (Ertel et al. in Am J Public Health 98:1215-1220, 2008), practices that prohibit social interaction threaten human well-being. For persons who have Alzheimer's disease (AD), social interaction continues to play an integral part in cognitive function and delays in memory loss, according to a longitudinal study of social networks (Bennett et al...
February 2010: Language Policy
Xiongwei Zhu, Hyoung-gon Lee, George Perry, Mark A Smith
Given the relative modality of single-insult models to accurately reflect Alzheimer disease pathogenesis, based on studies on mitogenic and oxidative stress signaling pathways, we proposed a two-hit hypothesis 2 years ago stating that both oxidative stress and mitogenic dysregulation are necessary and sufficient to cause the disease and suggested that it may be a common mechanism for other neurodegenerative diseases as well (X. Zhu, A.K. Raina, G. Perry, M.A. Smith, Alzheimer's disease: the two-hit hypothesis, Lancet Neurol...
April 2007: Biochimica et Biophysica Acta
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"